Pneumocystis carinii pneumonia after the discontinuation of secondary prophylaxis

被引：5

作者：

Degen, O ^{[1
]}

ven Lunzen, J

Horstkotte, MA

Sobottka, I

Stellbrink, HJ

机构：

[1] Univ Klinikum Hamburg, Med Kernklin & Poliklin, Hamburg, Germany

[2] Univ Klinikum Hamburg, Inst Mikrobiol & Immunol, Hamburg, Germany

来源：

AIDS | 2002年 / 16卷 / 10期

关键词：

D O I：

10.1097/00002030-200207050-00021

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：1433 / 1434

页数：2

共 10 条

[1] A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. [J].

de Quiros, JCLB ;

Miro, JM ;

Pena, JM ;

Podzamczer, D ;

Alberdi, JC ;

Martínez, E ;

Cosin, J ;

Claramonte, X ;

Gonzalez, J ;

Domingo, P ;

Casado, JL ;

Ribera, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (03) :159-167

[2]

Jones J L, 1999, MMWR CDC Surveill Summ, V48, P1

[3] Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy? [J].

Kirk, O ;

Lundgren, JD ;

Pedersen, C ;

Nielsen, H ;

Gerstoft, J .

AIDS, 1999, 13 (13) :1647-1651

[4] A prospective study of discontinuing primary and secondary Pneumocystis carinii pneumonia prophylaxis after CD4 cell count increase to > 200 X 106/I [J].

Koletar, SL ;

Heald, AE ;

Finkelstein, D ;

Hafner, R ;

Currier, JS ;

McCutchan, JA ;

Vallee, M ;

Torriani, FJ ;

Powderly, WG ;

Fass, RJ ;

Murphy, RL .

AIDS, 2001, 15 (12) :1509-1515

[5] Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. [J].

Ledergerber, B ;

Mocroft, A ;

Reiss, P ;

Furrer, H ;

Kirk, O ;

Bickel, M ;

Uberti-Foppa, C ;

Pradier, C ;

Monforte, AD ;

Schneider, MME ;

Lundgren, JD .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (03) :168-174

[6] Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: Results from the EuroSIDA study [J].

Miller, V ;

Mocroft, A ;

Reiss, P ;

Katlama, C ;

Papadopoulos, AI ;

Katzenstein, T ;

van Lunzen, J ;

Antunes, F ;

Phillips, AN ;

Lundgren, JD .

ANNALS OF INTERNAL MEDICINE, 1999, 130 (07) :570-577

[7] Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection [J].

Palella, FJ ;

Delaney, KM ;

Moorman, AC ;

Loveless, MO ;

Fuhrer, J ;

Satten, GA ;

Aschman, DJ ;

Holmberg, SD .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (13) :853-860

[8] Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy [J].

Schneider, MME ;

Borleffs, JCC ;

Stolk, RP ;

Jaspers, CAJJ ;

Hoepelman, AIM .

LANCET, 1999, 353 (9148) :201-203

[9]

*USPHS IDSA, 2001, HIV CLIN TRIALS, V2, P493

[10] Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection [J].

Weverling, GJ ;

Mocroft, A ;

Ledergerber, B ;

Kirk, O ;

González-Lahoz, J ;

Monforte, AD ;

Proenca, R ;

Phillips, AN ;

Lundgren, JD ;

Reiss, P .

LANCET, 1999, 353 (9161) :1293-1298

← 1 →